SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is experiencing intense volatility and a sharp pullback, largely attributed to the CME Group's increased margin requirements for silver derivatives, leading to forced liquidations and margin calls. The community is fiercely divided, with bulls viewing this as a significant "buy the dip" opportunity driven by strong industrial demand and global supply shortages. Conversely, bears see this as a "blow-off top" and the unwinding of a speculative rally, citing historical parallels and concerns about market manipulation.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics (AQST) is heavily trending as the PDUFA date for its innovative Anaphylm oral epinephrine film rapidly approaches, driving significant community discussion. Investors are largely bullish, citing strong clinical data and the absence of an FDA Advisory Committee meeting as key de-risking factors for the needle-free treatment. However, high short interest and a pending competitor's citizen petition are also fueling debate around potential market volatility and approval outcomes.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is currently trending following positive preliminary data from the open-label arm of its Phase 3 FLAMINGO-01 trial, reporting an 80% reduction in breast cancer recurrence. This clinical de-risking, along with the CEO's continued insider buys and strategic financing, is igniting intense community chatter about a potential short squeeze due to extremely high borrow rates. Investors are keenly anticipating further updates that could lead to non-dilutive partnerships or a significant buyout, as the company's HER2+ breast cancer immunotherapy gains momentum.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

The SPDR Gold Shares ETF (GLD) is currently a major talking point after experiencing a sharp pullback from recent highs in precious metals, heavily influenced by the CME Group's increased margin requirements for futures contracts. This action is widely debated, with some in the community viewing it as a deliberate 

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

Alpha Capital Acquisition Co (ASPC) is trending due to immense speculative interest and extreme volatility, driven by its low float. The community is actively pushing for a short squeeze, with many comparing its rapid price action and frequent trading halts to past explosive movers like SMX and HKD, while also cautioning about its highly speculative nature.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending following its inclusion in the Russell 2000 and 3000 indexes, despite persistent selling pressure and accusations of market manipulation. Community sentiment is sharply divided, with bulls highlighting the company's profitability and comparing it to early Robinhood, while bears point to significant price depreciation and dilution concerns, frequently linking its performance to broader crypto market movements.

ProShares Trust - ProShares UltraShort Silver -2x Shares

ProShares UltraShort Silver

ProShares UltraShort Silver (ZSL) is trending as silver experiences a sharp decline, largely driven by increased margin requirements from the CME. The community is actively capitalizing on this pullback, with many celebrating profits from their short positions and anticipating further downside for silver. This reflects a broader sentiment that silver's recent rapid ascent was overextended and ripe for a significant correction.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver is trending due to widespread community discussion surrounding China's impending 2026 silver export ban, which many anticipate will create a significant supply shock. This speculation, alongside a notable price disconnect between Eastern and Western markets, is fueling bullish predictions for massive long-term gains driven by industrial demand. However, a strong contingent of traders is warning of an overbought market susceptible to profit-taking and potential price manipulation in the short term.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively trending as the community debates its near-term prospects, buoyed by recent analyst upgrades and anticipation of potential announcements at the upcoming CES 2026. Bulls highlight the company's strong voice AI technology, zero debt, and significant contractual backlog, while skeptics express frustration over insider selling and persistent price volatility. This dynamic fuels a sharp divergence in sentiment, with discussions centered on whether fundamental strengths can overcome market manipulation concerns.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx (RARE) is sharply trending lower after its Phase 3 trials for Setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints for fracture reduction, causing a significant stock plunge. The community is actively debating if the steep decline is an overreaction and a buying opportunity given the company's existing approved drugs and pipeline, while others express concern over the program's future amidst planned cost reductions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$VG time for some fundamental analysis.  With the help of Gemini AI, this table shows the potential benefits of efforts to increase capacity above nameplate at Plaquemines.  It dramatically lowers the cost of production by $0.50-$1.90/MMBtu for the life of the facility.   
 
Think this is hypothetical hogwash?  Well, S&amp;P Global incorporated higher than nameplate capacity in its recent Plaquemines debt analysis.   
 
&quot;Based on performance to date, we have modeled excess capacity of 4 MTPA above the nameplate capacity of 20 MTPA. This amount represents the incremental capacity that has been fully approved and which the independent engineer has indicated is supported by production to date. We note that the independent engineer has indicated that the plant can produce 28 MTPA on a sustainable basis.&quot; 
 
Read the S&amp;P report via link below.   
https://www.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3497508

Cheesecakes

Winter Storm

Spglobal

Research Update: Venture Global Plaquemines LNG L | S&P Global Ratings

StockTwits Web

Venture Global Inc

 time for some fundamental analysis.  With the help of Gemini AI, this table shows the potential benefits of efforts to increase capacity above nameplate at Plaquemines.  It dramatically lowers the cost of production by $0.50-$1.90/MMBtu for the life of the facility.   
 
Think this is hypothetical hogwash?  Well, S&P Global incorporated higher than nameplate capacity in its recent Plaquemines debt analysis.   
 
"Based on performance to date, we have modeled excess capacity of 4 MTPA above the nameplate capacity of 20 MTPA. This amount represents the incremental capacity that has been fully approved and which the independent engineer has indicated is supported by production to date. We note that the independent engineer has indicated that the plant can produce 28 MTPA on a sustainable basis." 
 
Read the S&P report via link below.   
